…
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -64.36M | -115.55M | -135.89M | -62.09M | -13.77M |
| Net income | -66.42M | -115.55M | -135.89M | -62.09M | -13.83M |
| Selling general administrative | 427.32M | 237.31M | 80.33M | 44.95M | 25.40M |
| Gross profit | 420.68M | 170.13M | 15.85M | 24.86M | 54.95M |
| Reconciled depreciation | 1.82M | 1.23M | 0.63M | 0.33M | 0.31M |
| Ebit | -55.42M | -107.70M | -132.55M | -62.71M | -12.16M |
| Ebitda | -53.61M | -106.48M | -131.67M | -59.13M | -10.58M |
| Depreciation and amortization | 1.82M | 1.23M | 0.88M | 3.58M | 1.58M |
| Non operating income net other | - | - | - | -0.68M | -1.65M |
| Operating income | -70.97M | -120.57M | -143.16M | -62.71M | -12.16M |
| Other operating expenses | 522.33M | 303.52M | 160.60M | 88.53M | 69.18M |
| Interest expense | 8.94M | 7.45M | 3.23M | 2.20M | 2.88M |
| Tax provision | 2.06M | 0.00M | 0.00M | -0.00M | 0.06M |
| Interest income | 15.75M | 15.01M | 9.49M | 3.50M | 0.04M |
| Net interest income | 6.81M | 7.17M | 6.44M | 1.30M | 0.04M |
| Income tax expense | 2.06M | - | 0.71M | -0.00M | 0.06M |
| Total revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M |
| Total operating expenses | 491.64M | 290.70M | 159.01M | 87.57M | 67.11M |
| Cost of revenue | 30.68M | 12.83M | 1.59M | 0.95M | 2.08M |
| Total other income expense net | 6.61M | 5.01M | 7.26M | 0.62M | -1.61M |
| Net income from continuing ops | -66.42M | -115.55M | -107.59M | -62.09M | -13.83M |
| Net income applicable to common shares | - | - | - | -62.09M | -13.83M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 562.16M | 376.99M | 266.22M | 227.86M | 178.91M |
| Intangible assets | 7.37M | 8.33M | 3.87M | - | - |
| Other current assets | 14.03M | 14.65M | 7.87M | 0.00M | 4.04M |
| Total liab | 218.73M | 152.46M | 69.24M | 34.96M | 12.18M |
| Total stockholder equity | 343.43M | 224.53M | 196.99M | 192.90M | 166.73M |
| Other current liab | 119.31M | 52.27M | 18.39M | 4.80M | 1.49M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -426.63M | -360.21M | -244.66M | -108.76M | -46.67M |
| Other liab | - | - | - | 0.05M | 0.11M |
| Other assets | - | - | 0.00M | 0.48M | 0.18M |
| Cash | 183.64M | 94.82M | 224.95M | 71.66M | 171.33M |
| Total current liabilities | 135.69M | 80.61M | 36.94M | 15.43M | 11.48M |
| Net debt | -90.00M | -22.37M | -193.22M | -51.51M | -169.44M |
| Short term debt | - | 0.61M | 0.40M | 0.72M | 1.31M |
| Short long term debt total | 93.64M | 72.45M | 31.73M | 20.16M | 1.89M |
| Other stockholder equity | 769.67M | 584.56M | 441.64M | 301.73M | 213.40M |
| Property plant equipment | - | - | - | 0.96M | 0.76M |
| Total current assets | 522.78M | 356.70M | 256.13M | 225.38M | 175.95M |
| Long term investments | 3.87M | 3.00M | 0.63M | 0.37M | - |
| Net tangible assets | - | - | - | 192.90M | 166.73M |
| Short term investments | 233.63M | 196.56M | 2.50M | 145.37M | 0.48M |
| Net receivables | 87.11M | 48.06M | 17.71M | 3.58M | 0.09M |
| Long term debt | 72.44M | 71.84M | 29.82M | 19.43M | - |
| Inventory | 4.37M | 2.62M | 3.11M | 4.76M | 175.68M |
| Accounts payable | 16.39M | 27.74M | 18.15M | 9.91M | 8.68M |
| Accumulated other comprehensive income | 0.38M | 0.18M | -0.00M | -0.07M | - |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Retained earnings total equity | - | - | - | -108.76M | -46.67M |
| Non currrent assets other | 6.39M | 6.09M | 1.51M | 0.58M | 1.13M |
| Non current assets total | 39.38M | 20.29M | 10.09M | 2.49M | 2.96M |
| Capital lease obligations | 0.00M | 0.61M | 0.40M | 0.77M | 1.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -32.26M | -199.19M | 35.53M | -144.12M | -0.59M |
| Change to liabilities | - | - | - | 3.48M | 5.75M |
| Total cashflows from investing activities | -42.12M | -199.19M | 140.60M | -144.63M | -0.59M |
| Net borrowings | 0.00M | 75.00M | 10.00M | -0.88M | 20.00M |
| Total cash from financing activities | 143.39M | 154.66M | 130.18M | 93.99M | 0.02M |
| Change to operating activities | - | - | - | -1.77M | -2.44M |
| Net income | -66.42M | -115.55M | -135.89M | -62.09M | -13.83M |
| Change in cash | 88.82M | -127.57M | 153.29M | -99.67M | 3.18M |
| Begin period cash flow | 97.38M | 224.95M | 71.66M | 171.33M | 168.15M |
| End period cash flow | 186.20M | 97.38M | 224.95M | 71.66M | 171.33M |
| Total cash from operating activities | -12.45M | -83.03M | -117.49M | -49.03M | 3.75M |
| Issuance of capital stock | 134.77M | 98.29M | 99.38M | 74.35M | 0.00M |
| Depreciation | 1.82M | 1.23M | 0.88M | 0.33M | 0.31M |
| Other cashflows from investing activities | - | -5.00M | -4.00M | - | - |
| Change to inventory | -1.75M | -2.05M | -3.11M | - | - |
| Change to account receivables | -39.05M | -30.14M | -14.13M | - | -0.07M |
| Sale purchase of stock | - | - | - | 74.94M | 0.32M |
| Other cashflows from financing activities | 143.39M | -18.63M | 1.58M | 19.64M | -5.47M |
| Change to netincome | - | - | - | 13.96M | 15.00M |
| Capital expenditures | 9.86M | 1.57M | 5.50M | 0.51M | 0.59M |
| Change receivables | - | - | - | -3.49M | -0.07M |
| Cash flows other operating | - | - | - | -0.20M | -3.42M |
| Cash and cash equivalents changes | - | - | - | -99.67M | 3.18M |
| Change in working capital | 14.64M | 3.84M | 0.31M | -0.95M | 1.37M |
| Stock based compensation | 41.72M | 27.82M | 19.83M | 13.46M | 8.46M |
| Other non cash items | -4.21M | -0.36M | -2.61M | 0.23M | 5.79M |
| Free cash flow | -22.31M | -84.59M | -123.00M | -49.54M | 3.16M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals Inc |
-4.66 6.00% |
73.01 | - | 73.53 | 6.04 | 10.79 | 5.55 | -3.23 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Bobak R. Azamian M.D. | Co-Founder, Pres, CEO & Chairman | NA |
| Dr. Bryan Wahl J.D., M.D. | Gen. Counsel & Corp. Sec. | 1978 |
| Ms. Dianne C. Whitfield M.S.W. | Chief HR Officer | 1977 |
| Dr. Elizabeth Yeu Lin M.D. | Chief Medical Advisor & Director | 1978 |
| Dr. D. Michael Ackermann Ph.D. | Consultant | 1982 |
| Mr. Leonard M. Greenstein J.D. | Chief Financial Officer | 1976 |
| Dr. Seshadri Neervannan Ph.D. | Chief Operating Officer | 1968 |
| Mr. David Nakasone | Head of Investor Relations | NA |
| Ms. Adrienne Kemp | Sr. Director of Corp. Communications | NA |
| Mr. Matthew Rossen M.B.A. | VP of Marketing | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.